Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05963282 · ClinicalTrials.gov registry record
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,870
- Enrollment target
NCT05963282 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,870 participants.
The verdict
NCT05963282 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,870 participants
- Enrollment target
Study Summary
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,870 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2022-07-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05963282
The ClinicalTrials.gov registry entry for NCT05963282 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,870 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05963282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05963282 about?
NCT05963282 is a clinical study titled "Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients". This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin re...
What is the current status of trial NCT05963282?
This trial is currently completed. The enrollment target is 9,870 participants. The study started on 2021-11-29. Estimated completion is 2022-07-19.
Who is sponsoring clinical trial NCT05963282?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.